NEW YORK, July 30 – Microbial genomics company Microcide Pharmaceuticals said Monday it had signed an agreement to acquire Althexis in an effort to step-up its drug discovery capabilities.

Microcide of Mountain View, Calif., and Althexis of Waltham, Mass., also announced that the combined company would receive $60 million in a private round of financing. Prospect Venture Partners, New Enterprise Associates, and Schroder Ventures are particpating in the placement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.